Biogen Sets $750,000 Initial Price For First-Ever Spinal Atrophy Drug

[Updated, 12/29/16, see below] Patients with spinal muscular atrophy got some good news last week when the FDA approved nusinersen (Spinraza), making it the first marketed drug ever for the rare and potentially deadly genetic disease. But as expected, the drug, from Biogen and Ionis Pharmaceuticals, is a costly one, priced at the high end … Continue reading Biogen Sets $750,000 Initial Price For First-Ever Spinal Atrophy Drug